17 Aug
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development
31 May
Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
- Phase 3 DISSOLVE I and DISSOLVE II studies both met their primary efficacy endpoints, with SEL-212-treated patients demonstrating statistically significant higher response rates compared to placebo - - SEL-212 was observed to have a favorable safety profile and was well-tolerated across both
04 May
Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported positive data from Phase 3 DISSOLVE program of SEL-212 in chronic refractory gout;
28 Apr
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
WATERTOWN, Mass. , April 28, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences , Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today  announced that it plans to host a
21 Mar
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint
--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II --75% of subjects in the DISSOLVE I extension phase on active treatment
02 Mar
Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 - -   Continue to enroll patients in   ReiMMAgine , the   Phase 1/2 clinical trial of SEL-302 for the treatment of methylmalonic acidemia (MMA)  - - IND enabling studies
23 Feb
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update
WATERTOWN, Mass. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference
07 Feb
Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
WATERTOWN, Mass. , Feb. 07, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that Company’s Management will
09 Jan
Selecta Biosciences Provides Business Update and Outlook for 2023
- Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in chronic refractory gout in Q1 2023 - - To receive $10 million upfront for the execution of a license agreement for Xork, the Company’s next-generation immunoglobulin G (IgG) protease candidate, to be developed with Astellas
09 Jan
Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease
Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies' product, for the treatment of Pompe Disease Selecta to receive a $10M upfront payment and eligible to receive up to $340M for certain additional development and